FDA approves PharmaJet Stratis injector for delivery of Afluria

KING OF PRUSSIA, Pa. — PharmaJet, the developer of a needle-free injection technology to administer medications and vaccines to patients, and bioCSL, the maker of Afluria (influenza vaccine) on Tuesday announced the Food and Drug Administration has approved the PharmaJet Stratis 0.5mL Needle-Free Jet Injector for delivery of Afluria in individuals ages 18 years to 64 years. This is the first needle-free delivery system approved by the FDA for the administration of an inactivated influenza vaccine, the companies reported.

 

“Healthcare providers now have the option of delivering Afluria without a needle,” stated Ron Lowy, PharmaJet CEO and co-chairman. “The PharmaJet injection technology is an especially important innovation for the millions of individuals who suffer from fear of needles and who consequently forego their annual flu vaccination. We believe this is a significant step forward in the effort to improve public health through broader immunization coverage, as well as improved safety of caregivers.”

 

The PharmaJet injector delivers the vaccine by means of a narrow, precise fluid stream that penetrates the skin in about one-tenth of a second. “The importance of being vaccinated yearly against seasonal influenza cannot be overstated,” commented Marie Mazur, president of bioCSL. “PharmaJet’s needle-free technology, when used to administer Afluria, could play a significant role in increasing adult vaccination rates by helping to personalize vaccine delivery.”